Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Madrigal Pharmaceuticals (MDGL) Shares Outstanding (2018 - 2025)

Madrigal Pharmaceuticals has reported Shares Outstanding over the past 14 years, most recently at $22.8 million for Q4 2025.

  • Quarterly Shares Outstanding rose 3.81% to $22.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.8 million through Dec 2025, up 3.81% year-over-year, with the annual reading at $22.8 million for FY2025, 3.81% up from the prior year.
  • Shares Outstanding was $22.8 million for Q4 2025 at Madrigal Pharmaceuticals, up from $22.7 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $22.8 million in Q4 2025 and troughed at $2.0 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $17.6 million (2021), against an average of $15.5 million.
  • Year-over-year, Shares Outstanding plummeted 88.13% in 2022 and then skyrocketed 858.07% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $17.1 million in 2021, then rose by 5.84% to $18.1 million in 2022, then increased by 9.79% to $19.9 million in 2023, then rose by 10.71% to $22.0 million in 2024, then grew by 3.81% to $22.8 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Shares Outstanding are $22.8 million (Q4 2025), $22.7 million (Q3 2025), and $22.2 million (Q2 2025).